Might a Chemical from Celery and Broccoli One Day Yield a New Drug to Prevent Breast Cancer Metastasis?

A natural phytochemical found in broccoli may help lower the risk of metastasis in women with triple-negative breast cancer.
A natural phytochemical found in broccoli may help lower the risk of metastasis in women with triple-negative breast cancer.

Luteolin, a natural phytochemical found in thyme, parsley, celery and broccoli, might reduce the risk of lung metastasis in women with triple-negative breast cancer (TNBC), according to researchers at the University of Missouri in Columbia, Missouri.1

TNBC cells lack 3 key receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2/neu). The absence of these receptors from TNBC cells renders them impervious to common cancer chemotherapy drugs and quicker to metastasize to distant organs such as the lungs.

Studying human TNBC xenografts in mice prone to develop metastatic TNBC tumors in the lungs, the research team found that luteolin injections significantly reduced metastasis in the lungs, usually without weight loss — an indicator that the luteolin was nontoxic to the animals.

In vitro cell line experiments subsequently showed that luteolin inhibits TNBC cell migration.

Additional preclinical studies are planned. If successful, the researchers will seek investigative new drug status for luteolin and begin human clinical trials.

Reference

1. Cook MT, Liang Y, Besch-Williford C, Hyder SM. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer: Targets and Therapy. 2017;9:9-19. doi: 10.2147/BCTT.S124860

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs